Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.

被引：0

作者：

Powles, Thomas

Cislo, Paul

Kirker, Melissa

Chang, Jane

Gharibian, Norbek

Thompson, Allison

Costa, Nuno

Grivas, Petros

机构：

[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, Expt Canc Med Ctr, London, England

[2] Pfizer, New York, NY USA

[3] Pfizer, Porto Salvo, Portugal

[4] Univ Washington, Seattle, WA 98195 USA

[5] Fred Hutchinson Canc Ctr, Seattle, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4515

引用

页数：1